INTRODUCTION {#S1}
============

DNA-protein crosslinks (DPCs) are a form of DNA damage generated when a protein moiety is covalently conjugated to cellular DNA. The exceedingly bulky nature of DPCs poses impassible barriers to essential DNA transactions, including replication, transcription, and recombination. DPCs are cytotoxic and mutagenic and lead to a destabilized genome ([@R22]; [@R48]). Cellular mechanisms of DPC repair are increasingly gaining attention, especially with the characterization of an inheritable, cancer-prone premature aging disease originating from DPC repair deficiencies ([@R19]; [@R22], [@R23]). Exogenous and endogenous DNA-damaging agents generating nuclear DPCs are also abundant ([@R3]; [@R9]; [@R17]; [@R30]; [@R51]). However, in-depth understanding of the molecular mechanism(s) of DPC repair is lagging behind, not only because of the complexity of the repair process but also due to limited experimental readouts for monitoring cellular DPC repair.

Genotoxic DPCs arise from two distinct mechanisms: enzymatic DPCs and non-enzymatic DPCs. DNA metabolic and modifying enzymes, such as topoisomerases (TOPs), DNA polymerases, and DNA methyltransferases, form transient covalent intermediates with DNA. These catalytic intermediates can become interminable by mutations in the catalytic domain of the enzyme ([@R2]), by aberrant DNA substrates ([@R36]), or by inhibitors that stabilize covalent enzyme-DNA transient structures ([@R13]; [@R42]). For example, DPCs form efficiently from entrapped TOP1 and TOP2 cleavage complexes (TOP1cc and TOP2cc, respectively), which are produced by several broadly used cancer chemotherapy drugs such as doxorubicin, camptothecin (CPT), and etoposide (ETO) ([@R8]; [@R33]; [@R32]). These topoisomerase poisons trap TOP1 and/or TOP2 by intercalating into the interface between DNA and the enzymes and consequently prevent re-ligation of the strand breaks, forming stabilized cleavage complexes, which are repaired by tyrosyl-DNA phosphodiesterase 1 and 2 (TDP1 and TDP2) ([@R33]).

Non-enzymatic DPCs are generated by a large variety of endogenous and exogenous agents. Ionizing radiation, ultraviolet light, certain transition metal ions, and reactive compounds, including reactive aldehydes, are capable of covalently conjugating proteins onto DNA through primary amine groups on amino acid and nucleotide residues ([@R9]; [@R13]; [@R17]). Notably, formaldehyde (FA), with its widespread environmental presence and constant intracellular presence ([@R49]; [@R51]; [@R53]), is a potent crosslinking agent and a demonstrated carcinogen ([@R34]; [@R45]). Formaldehyde-induced DPCs have been widely used as a model lesion for studying the cellular pathways of DPC repair ([@R10]; [@R16]). Bifunctional alkylating drugs, such as cisplatin, are also capable of inducing non-enzymatic DPCs ([@R24]).

Current approaches for assaying cellular DPCs fall into two categories of direct or indirect measurements. Upon separating protein-crosslinked DNA from free DNA, the direct measurement method quantifies the amount of proteins associated with DNA. This is accomplished by the general detection of proteins via fluorescent labeling. For a particular protein of interest, antibody-based detection is used to assess the amount of DNA-tethered target protein ([@R14]; [@R26]; [@R28]; [@R41]; [@R43]).

An indirect assay of DPCs relies on isolating and measuring the amount of protein-bound DNA and calculating its proportion in total DNA as a quantitative reflection of DPCs ([@R5]; [@R42]; [@R55]). The K-SDS assay is the conventional platform of indirect DPC measurement. To isolate protein-tethered DNA, SDS is used to dissolve chromatin preparations. Free proteins and DPCs are converted to the precipitated form by the addition of potassium chloride while free DNA remains soluble ([@R47]). DNA contained in DPCs is released by proteinase digestion to remove the protein moiety. Normalizing the amount of DPC-associated DNA against total sample DNA yields the percentage of genomic DNA bearing DPCs ([@R5]; [@R6]; [@R20]; [@R26]; [@R31]; [@R43], [@R44]; [@R50]; [@R52]; [@R55]).

The advantage of the direct DPC assay is that the absolute amount of DNA-linked proteins is determined collectively. However, the process of isolating DNA-tethered proteins from free proteins necessitates repeated CsCl gradient purification and dialysis, which render the procedure lengthy and increases the potential for inconsistency. The K-SDS-based indirect DPC assays are straightforward and better suited to handling a large number of samples. One major unfavorable aspect, however, is the high level of background and, accordingly, moderate signal:noise ratio ([@R20]; [@R26]; [@R31]; [@R52]). In the canonical rapid approach to DNA adduct recovery (RADAR) assay, wherein an antibody is used to detect the DNA-bound protein target, the ethanol precipitation that removes free proteins leads to background issues, and resolution is dependent on the specificity of the antibody ([@R14]). DPC isolation using the RADAR procedure can be resolved by SDS-PAGE for the quantification of global DPCs ([@R50]).

Attempts to increase the signal:background ratio of the current DPC assays have been described in a number of studies. These include the addition of an RNA digestion step to lower the background DNA reading or the resolution of the DPC samples by gel electrophoresis to reduce free DNA contamination. These additional steps had varying degrees of effectiveness, but success in mitigating the high background level of the K-SDS assay was limited ([@R26]; [@R43]; [@R50]). In most published K-SDS experiments, the background DPC reading in unperturbed cells is set at 1. Those reported as absolute DPC coefficient can reach as high as 10% and the fold change under physiological doses of DPC-inducing agents is generally \<5-fold, restricting the application of this method ([@R1]; [@R20]; [@R31]; [@R52]).

Given the advantages and limitations of each DPC assay, improving the signal:background ratio while maintaining the simplicity and consistency of the protocol is highly desirable. In this study, we established a novel procedure of DPC analysis by significantly elevating the stringency of DPC isolation conditions. This new assay, designated ARK (for advanced recovery of K \[potassium\]-SDS precipitates), increased the readout range of DPC quantification by 5-fold. The simplicity of this assay is similar to that of the current indirect assays and is capable of processing a large number of samples compared to the CsCl gradient-based direct assay. Here, we demonstrate the effectiveness of the ARK assay in detecting exogenous DPCs induced by formaldehyde and topoisomerase inhibition. Using the ARK assay, we detected impaired DPC repair in mutants with disrupted FANCL, suggesting a role for the Fanconi anemia pathway in the repair of DPCs. Thus, this new assay provides a much-improved tool for studying DPC repair mechanisms as well as studies regarding DPC-inducing agents.

RESULTS {#S2}
=======

Design of the New ARK Assay {#S3}
---------------------------

An effective approach to improve an indirect DPC assay is to reduce the background while retaining positive signals. We designed the ARK method with several measures to reduce the background reading and improve the recovery of DPCs ([Figure 1](#F1){ref-type="fig"}). We used guanidine thiocyanate (GTC) for cell lysis to apply a stringent condition to eliminate noncovalent DNA-protein association, which constitutes a major source of background. Subsequent to the 50% ethanol cutoff precipitation, recovered DPCs together with free DNA and unbound proteins were dissolved in 1% SDS at denaturing temperature to further disrupt noncovalent DNA-protein associations. Following KCl-mediated precipitation to remove free DNA, the protein-bound DNA was released by proteinase K digestion and quantified against total genomic DNA to obtain the DPC coefficient.

In addition to the chaotropic- and detergent-based dissociation of noncovalent DNA-protein association, we tested several modifications that further reduce the background reading. Preparing the initial cell lysate with 55°C GTC buffer and shearing DPC samples in the 1% SDS buffer decreased the background reading in 293A and TK6 cells by \~61% ± 5.7% and \~67% ± 5.5%, respectively ([Figure 2A](#F2){ref-type="fig"}). To eliminate the potential interference of RNA in the ARK assay, we treated the DPC samples after proteinase K digestion with the mixed RNases A and T1. As shown in [Figure 2B](#F2){ref-type="fig"}, no detectable differences in DPC background readings were found in the presence or absence of RNase treatment in both HeLa and TK6 cell samples. This result indicates that the interference from RNA contamination is insignificant in the final DNA product of the ARK protocol.

In the conventional K-SDS assay, a final concentration of 0.4 mg/mL BSA is included to mitigate the potential interference of free SDS in the DNA samples. However, the presence of BSA is likely to interfere with the fluorometric detection of the PicoGreen assay. To test this, we analyzed the typical range of DPC DNA concentrations with and without the addition of BSA. We observed a significant decrease in the fluorometric readings from samples containing BSA (0.2 and 0.4 mg/mL) ([Figure 2C](#F2){ref-type="fig"}), indicating that the inclusion of BSA in the final DNA samples leads to reduced detection sensitivity. Thus, we eliminated the BSA addition in the K-SDS assay from our ARK assay. Furthermore, DNA purity from the ARK assay, as measured by the 260:280 nm absorbance ratio, is consistently at 1.9, suggesting that the ARK procedure yields DNA with sufficient purity for quantitative analysis.

Integrating the above modifications in the ARK assay design, we tested three model cell lines in direct comparison with the conventional K-SDS assay. Baseline DPC reading from three model cell lines--293A, HeLa, and TK6--were generated in parallel by the ARK assay and by the K-SDS assay, as shown in [Figure S1](#SD1){ref-type="supplementary-material"}. We found that the ARK protocol has consistently yielded a background DPC coefficient at \~1%, compared to the 8%--14% background readings from the K-SDS assay ([Figure S1](#SD1){ref-type="supplementary-material"}) ([@R20]). As a result, the ARK assay provides substantially increased sensitivity and detection range. When testing cells identically exposed to the LC20 dose of formaldehyde (400 μM, 2 h), folds of DPC induction by the ARK assay are 5.3 ± 0.69, 6.4 ± 0.28, and 5.1 ± 0.28 times higher than those obtained with the conventional K-SDS assay for 293A, HeLa, and TK6 cells, respectively ([Figure 2D](#F2){ref-type="fig"}). Moreover, the improved indirect DPC assay can be completed in \<7 h.

Detection of Nonenzymatic DPCs Using the ARK Assay {#S4}
--------------------------------------------------

To demonstrate the effectiveness of the ARK assay in the analysis of induced DPCs, we investigated DPC formation in response to treatment with varying doses of FA, a commonly used DPC-inducing agent. As shown in [Figure 3A](#F3){ref-type="fig"}, the ARK assay exhibited near-linear dose dependency in all three cell lines (293A, HeLa, TK6) tested within a physiologically relevant dose range ([@R31]; [@R50]). At a commonly adopted dose of 500 μM FA, the DPC coefficient fold increases in the three cell lines are approximately 23, 23, and 16 in 293A, HeLa, and TK6, respectively. In comparison, the conventional K-SDS assay typically exhibits a 3- to 4.5-fold increase at the same dose ([Figure 2D](#F2){ref-type="fig"}). Recently, a modified K-SDS assay by [@R26] obtained a DPC induction near 20-fold at 500 μM FA concentration in a serum-free medium. In contrast, the ARK assay was performed at the same dose but in the presence of 10% serum, with much reduced FA potency and allowed the experiment to be carried out at normal culture conditions and closer to a physiological dose range. These results suggest that the ARK assay provides a significantly expanded sensitivity and range of DPC detection, particularly at physiologically relevant doses.

To determine whether the ARK assay is capable of monitoring the kinetics of DPC repair, a time course study at 400 μM was performed to assess the removal of DPCs in 293A, HeLa, and TK6 cells ([Figure 3B](#F3){ref-type="fig"}). In 293A and HeLa cells, steady declines of DPCs were observed, and the level of residual DPCs reached the background level after 24 h of recovery time. In TK6 cells, \~30% of formaldehyde-induced DPCs remained at 24 h. This is consistent with published data that show that complete removal of DPCs from lymphocytes can take up to 3 days ([@R35]). The recovery curves generated by the ARK assay also matched the biphasic repair pattern, as observed with the CsCI-gradient-based DPC purification method ([@R41]). Approximately 60% DPCs in 293A and HeLa cells and 50% DPCs in TK6 cells were removed after 6 h, followed by a slower phase of DPC repair.

DPC half-life, derived from the ARK method, is 5 h for 293A and HeLa cells. This result is very consistent with the 4.8-h half-life as determined by the direct method using sensitive fluorescein isothiocyanate (FITC) labeling to measure DNA-conjugated proteins ([@R41]). To exclude the potential confounding factor of cell death during the time course, cell viability was determined at the corresponding time points for DPC detection. The highest variation of cell viability among all of the time points was \<18% ([Figure S2](#SD1){ref-type="supplementary-material"}), suggesting that cell death is not a significant factor in the DPC coefficient reading from the ARK assay. These results suggest that the ARK assay is of higher sensitivity and broader readout range than the present methods and that it is able to measure DPC repair comparable to the more complex direct assay.

Detection of Enzymatic DPCs Using the ARK Assay {#S5}
-----------------------------------------------

TOP inhibitors are a major class of enzymatic DPC-inducing agents, which account for nearly half of the present chemotherapeutic regimens. Among them, CPT and ETO are model agents for enzymatic DPCs by generating TOP1cc and TOP2cc. To determine whether the ARK assay is capable of measuring TOP1cc and TOP2cc, which are formed by 2 defined proteins, 293A, HeLa, and TK6 cells were exposed to serial doses of CPT for 1 h and analyzed by the ARK assay to obtain the DPC coefficient. As shown in [Figure 4A](#F4){ref-type="fig"}, typical dose-response patterns in the tested cell lines were observed. The dose-response approached a plateau at 20 μM for CPT, presumably at the point at which the TOP targets became saturated. At 10 μM CPT, a dose used in most cellular experiments, the increase in DPC coefficients from the 3 tested cell lines ranged from 12.3- to 15.3-fold, whereas the RADAR assay with similar treatment yielded a fold increase of \<10 ([@R14]).

Similarly, TOP2cc DPCs induced by ETO in the three tested cell lines exhibited typical dose-response curves, as measured by the ARK assay ([Figure 4B](#F4){ref-type="fig"}). The increase in DPC coefficients at the commonly used treatment concentration (20 μM) was 9.1- to 11.7-fold, while the dose range extended to 40 μM. These results suggest that the ARK assay is capable of detecting enzymatic DPCs with a comparable sensitivity and broad dose range of readout without relying on protein target-specific antibodies, allowing its application to a much broader range of enzymatic DPCs.

ARK Assay Validation Using DPC Repair-Deficient Genetic Models {#S6}
--------------------------------------------------------------

To validate the capability of the ARK assay in established genetic models, we analyzed DPC repair activities in TK6 and its isogenic *SPRTN* knockout mutant ([Figures S3A](#SD1){ref-type="supplementary-material"}--[S3C](#SD1){ref-type="supplementary-material"}). SPRTN possesses DNA-dependent proteolytic activity and is important for DPC repair in higher eukaryotes ([@R7]; [@R18]; [@R43], [@R44]; [@R50]). The DPC repair function of SPRTN appears to be non-redundant to the ubiquitination/proteasome degradation-mediated DPC processing ([@R18]; [@R44]). Thus, the *SPRTN* knockout mutant most likely exhibits partially, not fully, impaired DPC repair.

We exposed the parental TK6 cells and 2 independent knockout mutants, *SPRTN KO1* and *KO2*, to 400 μM FA for 2 h and measured the DPC removal at various time points. We found that both *SPRTN KO* mutants showed a significantly (p \<0.001 or 0.0001) higher level of DPC retention at all 3 time points compared to the wild-type TK6 cells ([Figure 5A](#F5){ref-type="fig"}). After 24 h of FA treatment, DPCs in wild-type TK6 cells decreased to 32.0% ± 5.0% of the initial level. The *SPRTN* mutants combined, however, retained an average of 70.3% ± 7.4% of the DPCs, which is 2.2-fold higher than the wild-type parental cells. This result shows that the ARK assay effectively detects the partial impairment of DPC repair from SPRTN deficiency.

In addition to the acute FA treatment, we analyzed DPC accumulation under continuous exposure of FA at a dose near mammalian plasma concentration (50 μM) ([@R38]). Following 12- and 24-h exposures to 50 μM FA, wild-type and *SPRTN* mutants were collected, and the amount of DPCs in each sample was analyzed by the ARK assay ([Figure 5B](#F5){ref-type="fig"}). In wild-type TK6 cells, the constant exposure to 50 μM FA resulted in a slight increase in DPC accumulation, suggesting that under physiological FA concentrations, wild-type TK6 cells possess a sufficient repair capacity to prevent the accumulation of DPCs. In the *SPRTN* mutants, the amount of accumulated DPCs in *KO1* and *KO2* showed a 3.2 ± 0.5-fold (p = 0.005) and a 4.9 ± 0.8-fold (p = 0.0001) increase at 12 h and a 2.5 ± 0.6-fold (p = 0.05) and a 3.9 ± 1.0-fold (p = 0.04) increase at 24 h, respectively, compared to the mock-treated samples. Lower levels of DPC accumulation at the 24-h time points are likely attributable to the diminishing potency of FA in the culture medium containing 10% serum. This result suggests that when exposed to plasma FA concentrations, loss of the *SPRTN* gene results in significantly increased DPC accumulation and that the ARK assay is capable of capturing such accumulation.

To validate the ARK assay in genetic models deficient in enzymatic DPC repair, we examined a *TDP1/TDP2* double knockout mutant (*TDP1/2*^−/−^) generated in the TK6 background ([Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}). TDP1 and TDP2 display redundant functions in TOP1cc and TOP2cc repair, respectively, by cleaving the enzyme-DNA phosphotyrosyl linkage ([@R54]). As a result, the loss of both genes impairs DPC removal and leads to the accumulation of TOP1cc and TOP2cc ([@R11]). We exposed the parental TK6 cells and the *TDP1/2*^−/−^ knockout mutant to 75 nM CPT and analyzed DPC coefficients after 12 and 24 h using the ARK assay. We found that DPC accumulation in wild-type TK6 cells at 12 and 24 h increased by 36.3% ± 5.2% and 39.7% ± 4.34%, respectively, compared to mock-treated samples. In the *TDP1/2*^−/−^ knockout cells, the DPC coefficients increased to 129.9% ± 11.1% and 160.7% ± 9.8%, respectively at 12 and 24 h ([Figure 5C](#F5){ref-type="fig"}). Thus, the ARK assay has detected a 3.6 ± 0.3-fold (p \< 0.001) and a 4.0 ± 0.2-fold (p \< 0.001) increase in DPCs as a result of *TDP1* and *TDP2* deletion. To verify that cell death resulting from DPC induction is not a significant confounding factor in the above results and that the doses of FA and CPT treatment are within physiological range, we analyzed cell viability at each time point ([Figure S4](#SD1){ref-type="supplementary-material"}). The results show that the cell viability changes in these experiments ([Figures 5A](#F5){ref-type="fig"}--[5C](#F5){ref-type="fig"}) were \<33%, 7%, and 30%, respectively. Therefore, cell death is not likely a significant factor in the DPC coefficient readings from the ARK assay. These data demonstrate that enzymatic DPCs can be effectively detected with a significant span of readout by the ARK assay.

Parallel Comparison between the ARK Assay and the RADAR Assay in the Detection of CPT-Induced DPCs {#S7}
--------------------------------------------------------------------------------------------------

Background level and signal recovery are two key aspects for both direct and indirect DPC assays. We have shown that the ARK assay has substantially improved sensitivity as an indirect DPC assay. To compare the capability of the ARK assay to direct DPC assay approaches, we performed a parallel comparison between the ARK assay and the RADAR assay. HeLa, 293A, and TK6 cells were treated or mock-treated with 10 μM CPT for 1 h. Cells were harvested and subjected to the standard RADAR assay. Results from the TOP1 antibody blotting produced 6.4 ± 2.0-, 4.1 ± 0.9-, and 10.0 ± 3.6-fold TOP1cc induction for 293A, HeLa, and TK6 cells, respectively ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}).

In parallel, identical cell preparations were analyzed using the ARK assay. As shown in [Figure 6C](#F6){ref-type="fig"}, the fold increases in TOP1cc induction are 13.4 ± 0.31, 12.2 ± 0.6, and 14.7 ± 2.1, for 293A, HeLa, and TK6 cells, respectively. This result suggests that the ARK assay can be more sensitive than the antibody-based RADAR assay in detecting TOP1cc DPCs.

To further test whether the ARK assay is capable of TOP1cc detection under an extended dose range, we treated 293A, HeLa, and TK6 cells with 2.5 μM CPT for 1 h and performed the ARK and RADAR assays in parallel on the same samples. The ARK assay detected an average DPC fold induction of 8.0 ± 0.15, 8.6 ± 0.74, and 8.5 ± 0.58 compared to 1.9 ± 0.44, 2.3 ± 0.20, and 2.0 ± 0.32 from the RADAR assay for 293A, HeLa, and TK6 cells, respectively ([Figure S5](#SD1){ref-type="supplementary-material"}). Results from these comparisons suggest that the ARK protocol for DPC detection is more sensitive in TOP1cc detection than the RADAR assay, with a lower dose range of CPT. These advantages render this new assay a versatile and reliable method in analyzing DPC repair activities under physiological conditions.

Removal of DPCs in Nucleotide Excision Repair and Fanconi Anemia Pathway-Deficient Cells {#S8}
----------------------------------------------------------------------------------------

The nucleotide excision repair (NER) pathway has been shown to repair DPCs with small protein moieties ([@R25]; [@R27]) or to act in the removal of DPC repair intermediates in which the bulkiness of the protein adducts is proteolytically reduced ([@R37]). The Fanconi anemia pathway has been implicated in DPC repair, as observed in Fanconi anemia pathway-deficient cells that accumulate DNA crosslinking damage arising from endogenous FA ([@R34]). Furthermore, cells deficient in the Fanconi anemia pathway are sensitive to DPC-inducing agents ([@R39]). To address the question of whether these distinct repair mechanisms contribute to DPC repair, we generated in HeLa cells an *XPA*^−/−^ mutant to serve as an NER-deficient model, an *FANCL*^−/−^ mutant to serve as a Fanconi anemia pathway-deficient model, and a double-knockout mutant for these genes to serve as a model deficient in both pathways ([Figures S6](#SD1){ref-type="supplementary-material"} and [S7](#SD1){ref-type="supplementary-material"}). When HeLa cells were exposed to FA, the formation of FANCD2 foci was observed in the wild-type but not in the *FANCL*^−/−^ mutant, reflecting the activation of the Fanconi anemia pathway ([Figure S7C](#SD1){ref-type="supplementary-material"}). Analyses of clonogenic survival ([Figure 7A](#F7){ref-type="fig"}) showed that the loss of XPA leads to a slight increase in FA sensitivity, while the deletion of FANCL drastically decreases cell survival. The *XPA*^−/−^/*FANCL*^−/−^ mutant exhibited a minute increase in sensitivity compared to the *FANCL*^−/−^ cells. These observations indicate that the NER mechanism has a limited function in FA-induced DNA crosslinking repair, while the Fanconi anemia pathway plays a more significant role in countering the genotoxicity from FA exposure.

To determine whether the clonogenic survival outcomes are connected to the DPC repair capacities of these mutants, we measured the DPC coefficient in the XPA and FANCL mutants using the ARK assay. *XPA*^−/−^, *FANCL*^−/−^, and *XPA*^−/−^/*FANCL*^−/−^ cells were subjected to an acute treatment of FA (500 μM) for 2 h, and the levels of protein-conjugated DNA were determined at 9 and 18 h after the treatment. As shown in [Figure 7B](#F7){ref-type="fig"}, the *XPA*^−/−^/*FANCL*^−/−^ and the *FANCL*^−/−^ mutants retained significantly higher and indistinguishable levels of DPCs compared to wild-type HeLa cells and the *XPA*^−/−^ mutant, suggesting that FANCL function contributes to DPC repair.

To validate the results derived from acute DPC induction, the mutant cells were treated with sustained exposure to low-dose formaldehyde (75 μM) for 6 and 12 h and followed by the ARK assay to determine the accumulation of DPCs. We found that the *XPA*^−/−^/*FANCL*^−/−^ and the *FANCL*^−/−^ mutants exhibited a markedly increased DPC level compared to the *XPA*^−/−^ mutant and wild-type HeLa cells. The relatively lower levels of DPC accumulation in *XPA*^−/−^/*FANCL*^−/−^ and *FANCL*^−/−^ mutants at the 12-h time point are likely attributable to the diminishing potency of FA in the culture medium and the presence of FANCL-independent repair mechanism(s). These results, which are consistent with the clonogenic survival data, suggest that the Fanconi anemia mechanism is involved in the removal of FA-induced DPC lesions.

DISCUSSION {#S9}
==========

In this study, we sought to develop a sensitive and versatile assay for the quantitative analysis of DPCs. The new assay, ARK, features a stringent DPC-isolation scheme that effectively reduced the background level of existing assays without signal loss. We showed that the ARK assay can detect both enzymatic and non-enzymatic DPCs with high sensitivity and expanded readout range. Analyses using DPC repair genetic models indicate that the ARK assay is effective in detecting their DPC repair defects. Moreover, the ARK assay retains the simplicity of the indirect DPC assay, allowing a large number of samples to be analyzed within 7 h.

Among the two categories of DPC assays, a direct assay quantifies DNA-conjugated proteins and an indirect assay measures protein-linked DNA as a percentage of total DNA. However, the isolation of DPCs is critical to both direct and indirect assays in terms of sensitivity and range of readout. A key factor in DPC isolation is the contamination from the noncovalent association between DNA and proteins. The main feature of the DPC isolation method in the ARK assay is the introduction of dual denaturation steps to minimize the noncovalent DNA protein complex, which is a major source of false DPC signals. The guanidine-mediated chaotropic lysis provides, in general, a more complete homogeneous cell lysis, which is capable of stripping most hydrogen bond- and charge-based DNA-protein associations from the abundance of chromatin proteins such as histones and high mobility group proteins. The resulting DPC isolate is further subjected to SDS-mediated protein denaturation, providing an additional and irreversible disruption of noncovalent DNA-protein association. Most likely, the dual denaturation steps and dual ethanol-KCl precipitation substantially decreases the amount of noncovalent DNA-protein complexes, allowing increased assay sensitivity and an extended readout range in the ARK assay ([Figure 2D](#F2){ref-type="fig"}).

Additional optimizations of DPC preparation contributed to the improved background reading and readout range of the ARK assay. We found that the background reading is reduced by \~2-fold when cells were lysed with heated guanidine buffer, presumably allowing more complete dissociation and denaturation of noncovalent protein binding to the DNA. Optimized shearing of DPC samples also decreases the background. As such, each step of the ARK assay has gone through optimization to achieve the \~10-fold improvement over the convention protocol.

From a technical standpoint, the ARK assay retains key advantages of the indirect assay, capable of global enzymatic and non-enzymatic DPC detection without relying on antibody detection and image-based quantifications. DPCs formed under physiological conditions can be readily and consistently detected from 100,000 cultured cells. The entire ARK protocol takes \<7 h to complete. The short assay duration and the procedural simplicity render the ARK assay capable of processing a large number of samples. The procedure can also assay tissue samples and be adapted to high-throughput purposes.

As an indirect assay, ARK provides effective measurement of global DPCs. For protein-specific DPC analysis, this assay may have its limitations. We showed that for TOP1cc, our protocol yielded comparable or much higher fold induction compared to the conventional RADAR assay ([Figures 6](#F6){ref-type="fig"} and [S5](#SD1){ref-type="supplementary-material"}). When assaying 5-aza-2′-deoxycytidine-induced DNA methyltransferase 1 DPCs ([@R14]), the induction fold from the ARK assay is 2.5 (data not shown), whereas the RADAR assay with the same samples can reach 3.0-fold ([@R14]). When combined with ELISA detection, the RADAR assay provides enhanced measurement of low abundant and protein-specific DPCs with high-quality antibodies ([@R15]).

Results from our study and others show that Fanconi anemia pathway mutant mice and cells are deficient in repairing FA-mediated crosslinking damage ([@R38]; [@R39]), which include DPCs and DNA interstrand crosslinks. Using the ARK assay, we show that DPC repair is impaired in Fanconi anemia mutant cells, supporting the notion that the Fanconi anemia pathway is involved in DPC removal and that the accumulation of DPC may account for, at least in part, the increased FA sensitivity of Fanconi anemia mutant cells. The ARK assay results also showed that the loss of XPA has a minimal impact on the accumulation of DPCs. This observation is consistent with the notion that the NER mechanism has a limited role in the overall DPC repair in mammalian cells ([@R12]). However, the Fanconi anemia pathway is unlikely the only mechanism for DPC removal, as reflected by our results, demonstrating that DPC removal is partially impaired in the *XPA*^−/−^/*FANCL*^−/−^ and *FANCL*^−/−^ mutants ([Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). SPRTN-dependent and proteasome-mediated DPC repair mechanisms have been shown to be independent of the Fanconi anemia mechanism ([@R18]). Given the highly variable nature of the protein adducts in DPCs, it is most likely that the repair of DPC lesions is carried out by multiple pathways with varying contributions in different cell types and conditions.

The ARK assay we describe here offers a novel and effective tool for quantitative DPC analyses. With markedly increased sensitivity, more questions regarding the formation, repair, and regulation of cellular DPCs can be experimentally addressed with this new methodology. Because the ARK provides a comprehensive measurement of cellular DPCs and does not rely on antibodies, its application on DPC repair biology extends to both enzymatic and non-enzymatic DPCs. Given the increasing interest in DPC repair biology and its direct connections to prevalent anti-cancer drugs, the ARK assay is expected to contribute to both basic and translational studies.

STAR★METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Lei Li (<leili@mdanderson.org>). All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Cell lines {#S13}

All cell lines used in this study were authenticated with STR marker using MD Anderson Cancer Center Cell Line Identify service (Institutional policy ACA \#1044) and tested negative for mycoplasma contamination using the MycoAlert Kit (Lonza). Human cell lines HeLa and 293A were purchased from American Type Culture Collection (ATCC) and Invitrogen, respectively, and both cell lines were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml penicillin-streptomycin. TK6 and its isogenic knockout mutants *SPRTN*^−/−^, *TDP1/2*^−/−^ (double knockout for both TDP1 and TDP2) were generated by the Takeda group and maintained in RPMI-1640 containing 10% horse serum, 2 mM glutamine, 100 U/ml penicillin-streptomycin, 1 mM sodium pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate. Cells were cultured at 37°C in a humidified incubator infused with 5% CO~2~.

HeLa cells are of female origin. Other cell lines, such as 293A and TK6 are of unknown gender origin.

METHOD DETAILS {#S14}
--------------

### Generation of SPRTN^−/−^ human TK6 cells {#S15}

To disrupt *SPRTN*, we designed a guide RNA, 5′-TCAAAAGGGGTTCGCTGAGACGG-3′, targeting the second exon and gene-targeting constructs. The arrangement of the CRISPR target site and integration cassette is depicted in [Figures S3A](#SD1){ref-type="supplementary-material"}--[S3C](#SD1){ref-type="supplementary-material"}. We generated two gene-targeting constructs containing the Neo^R^ or Puro^R^ marker using the Seamless Cloning and Assembly Kit (Thermo Fisher Scientific, US). The genomic DNA was amplified from TK6 cells with primers F1 and R1 (primer information is available in [Table S1](#SD1){ref-type="supplementary-material"}). The resulting PCR product was further amplified using primers F2 and R2 and primers F3 and R3 to obtain the 5′- and 3′-arms, respectively. The 5′ ends of the F2 and R2 primers have 20-nt sequences identical to the upstream and downstream of the *Apa*I site in both the DT-A-pA/loxP/PGK- Neo^R^-pA/loxP and DT-A-pA/loxP/PGK-Puro^R^-pA/loxP vectors (provided from the Laboratory for Animal Resources and Genetic Engineering, Center for Developmental Biology, RIKEN Kobe, <http://www2.clst.riken.jp/arg/cassette.html>) ([@R29]). The 5′ ends of the F3 and R3 primers have 20-nt sequences identical to the upstream and downstream of the *Afl*II site in these vectors. The DT-A-pA/loxP/PGK-Neo^R^-pA/loxP or DT-A-pA/loxP/PGK-Puro^R^-pA/loxP vectors were digested with both *Apa*I and *Afl*II, which cut at the 5′ and 3′ of the selection marker genes, respectively. We combined the digested DNAs containing either *Neo^R^* or *Puro^R^* marker with the 5′- and 3′-arms using the Seamless Cloning and Assembly Kit (Thermo Fisher Scientific, US), and generated the two gene-targeting constructs containing the *Neo^R^* or *Puro^R^* marker. 6 μg of CRISPR and 2 μg each of the two gene-targeting vectors were transfected into 4 × 10^6^ TK6 cells using the Neon Transfection System (Life Technologies, US) with three times 1350 V pulse with a 10 ms pulse width. After electroporation, cells were released into 20 mL drug-free medium containing 10% horse serum. Forty-eight hours later, cells were seeded into 96-well plates for selection with both G418 (Neomycin) and puromycin antibiotics for three weeks. The gene disruption was confirmed by genotyping PCR (using F4/F5 and R4 primers) and RT-PCR (using F6 and R5 primers) ([Figures S3A](#SD1){ref-type="supplementary-material"}--[S3C](#SD1){ref-type="supplementary-material"}).

### Generation of TDP1/2^−/−^ TK6 Cells {#S16}

To generate the double mutant of *TDP1*^−/−^/*TDP2*^−/−^, two targeting vectors and pX330-gRNA (the gRNA was inserted into the *BbsI* site of pX330 vector (Cat\# 42230, Addgene, US) ([@R4]) of TDP2 were transfected into *TDP1*^−/−^ mutant cells, which was described previously ([@R11]). To delete the *TDP2* gene, we generated a guide RNA, 5′-CCAAGAAGGTCCAAACTTCG-3′, targeting the catalytic site. The left and right arms were amplified using F7/R7 and F8/R8 primers, respectively ([Table S1](#SD1){ref-type="supplementary-material"}). The resulting fragments were assembled with either DT-ApA/NEO^R^ or DT-ApA/PURO^R^ having been digested with *ApaI* and *AflII*, using a GeneArt Seamless cloning kit (Invitrogen). Gene target events were confirmed by genomic PCR using two sets of primers (F4/R6 for NEO^R^ and F5/R6 for PURO^R^) and western blotting against anti-Tdp2 antibody (A302-737A, Bethyl) ([Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}).

### Generation of XPA^−/−^ and XPA^−/−^FANCL^−/−^ HeLa cells {#S17}

The *XPA*^−/−^ and *XPA*^−/−^*FANCL*^−/−^ mutant HeLa cell lines were generated on the wild-type and *FANCL*^−/−^ mutant background, respectively. The *FANCL*^−/−^ mutant was generated before as previously reported ([@R46]). gRNA targeting the XPA locus (5′-GGCGGCTTTAGAGCAACCCG-3′) inserted into lentiGuide-Puro (Addgene \#52963) and together with lentiCas9-Blast (Addgene \#52962) was used to infect *wild-type* or *FANCL*^−/−^ cells ([@R21]; [@R40]). Following selection, single cells were seeded in 96-well plates. Western blots were used to screen for XPA null clones (ThermoFisher Cat\# MS-650-P0). Candidate clones negative for XPA expression were subjected to genotyping to identify indels for both alleles. Ten or more clones of each genomic PCR fragment were sequenced to confirm the knockout genotype. The genetic identities of all mutant cell lines were validated by Sequenom Pro SNP fingerprinting.

### Drug treatment {#S18}

293A and HeLa cells were grown to 60%--70% confluence in 6-well plates and TK6 cells were maintained at 0.5 × 10^6^ cells/ml in 100-mm Petri dishes before treatment with formaldehyde for 2 hr and CPT or ETO for 1 hr. For dose-response studies, cells were collected immediately after the treatment. For time-course experiments of DPC repair, cells were treated with 400 μM of formaldehyde for 2 hr, washed, and replaced with fresh media. Cells were collected at different time points as needed. For DPC accumulation studies under low doses of formaldehyde and CPT, continuous treatment was carried out for either 12 hr or 24 hr before collection.

### Quantification of DNA by the PicoGreen dsDNA assay {#S19}

The assays were performed in a 96-well plate (Corning) following the manufacturer's instructions. The final total volume for each reaction/well was 250 μl. DNA standards of concentrations 8 ng, 80 ng, 400 ng, 800 ng, 1400 ng, 2000 ng/mL were prepared in a volume of 125 μL TE buffer and placed in the wells. Samples of proper volume, which was determined by fitting the best linear range, were diluted with TE buffer in the wells and adjusted to a final volume of 125 μl. Equal volume (125 μl) of the PicoGreen reagent diluted (1:200) from the original stock was added to the wells and mixed. Fluorescence detection was carried out on a Synergy2 plate reader (BioTek). The DNA quantity for each sample was derived from the fluorescence comparison with the standard curve. A control sample from a mock experimental well was used as a blank. The excitation and emission wavelengths were 485 nm and 528 nm, respectively. The detection protocol setting for Optics position was top 50% and the Gain was set at 50.

### Isolation of DPC-associated DNA by the ARK procedure {#S20}

To harvest cells, culture media was removed through aspiration directly from 6-well plates for adherent cells or after centrifugation (300 × *g* for 5 min) on the Thermo IEC CentraCL3 centrifuge for suspension cells. For 293A and HeLa 0.8 × 10^6^ cells and for TK6 2.5 × 10^6^ cells were lysed (without cell wash) in 950 μL of M buffer (MB) prewarmed at 55°C for 5-10 min. MB consists of 5.6 M GTC, 10 mM Tris--HCl (pH 6.5), 20 mM EDTA, 4% Triton X-100, 1% Sarkosyl, and 1% dithiothreitol. Cell lysates were collected after scraping and mild shearing with a 1-mL pipettip (passing 6 times). After a brief spin to eliminate bubbles, the lysates were further sheared by passing through a 22-gauge needle 6 times and followed by DNA precipitation with an equal volume of pre-chilled ethanol (−20°C). Free DNA and DPCs were recovered as a pellet after a full speed centrifugation (micro-centrifuge) at 4°C for 20 min. The pellet was washed at 4° C one time in the buffer composed of 20 mM Tris-HCl pH 6.5, 150 mM NaCl and 50% ethanol. Samples (no air drying) can either be stored at −80°C or used directly in the next step of the protocol. To dissolve the DNA/DPC pellet 0.5 mL of pre-warmed 1% SDS, 20 mM Tris-HCl (pH 7.5) was added and incubated at 42°C for 6 min. The samples were briefly spun (3500 × *g*, 30 s, on micro-centrifuge) and shorn by passing through a 25-gauge needle 5 times. As soon as 3-4 samples were processed, a 45 s full-speed centrifugation was performed to reduce the bubbles and 0.5 mL of 200 mM KCl, 20 mM Tris-HCl (pH 7.5) buffer was added to precipitate SDS-bound DPCs. The samples were incubated on ice for 6 min to complete the DPC precipitation. The precipitate was pelleted after a full-speed centrifugation for 5 min in cold room. The supernatant was collected and set aside on ice for DNA measurement. The DPC pellet was washed in 1.5 mL of 100 mM KCl, 20 mM Tris-HCl (pH 7.5) by incubating at 55°C for 10 min, on ice for 6 min, followed by centrifugation at 20,000 × *g* speed in a micro-centrifuge at 4°C for 5 min. The supernatant was collected and combined with the previously collected supernatant for total DNA measurement. The wash procedure was repeated one more time before dissolving the DPC pellet in 1 mL of the proteinase K buffer (100 mM KCl, 20 mM Tris-HCl, pH 7.5, and 10 mM EDTA). Proteins were digested by adding proteinase K to a final concentration of 0.2 mg/ml and incubating at 55°C for 45 min. The digestion was chilled on ice for 6 min and centrifuged at 20,000 × *g* for 10 min at 4°C to remove any debris. The 1 mL supernatant in this tube contains the DPC-associated DNA.

To determine the DPC coefficient, 10 μL from the 4 mL of the recovered free DNA supernatant, and 62.5 μL from the 1 mL supernatant of the DPC resuspension were used for DNA quantification by the PicoGreen assay kit. The DPC coefficient is expressed as the percentage of DNA from DPCs over the total DNA in each sample.

### K-SDS assay {#S21}

The K-SDS assay was performed by following the previously described non-isotopic protocol ([@R5]; [@R20]; [@R52]; [@R55]). Briefly, 0.8 × 10^6^ cells were collected through trypsinization, washed twice with ice-cold PBS, and resuspended in 100 μL PBS. The cells were lysed with 0.5 mL of a 2% SDS solution and the DNA was sheared by passing the lysates through a 22-gauge needle six times. The lysates were frozen at −80°C and thawed at 65°C for 10 min. An equal volume of 200 mM KCl, 20 mM Tris-HCl (pH 7.5) buffer was added to precipitate SDS-bound DPCs via incubation at 4°C for 6 min. After centrifugation at 6,000 × *g* for 5 min at 4°C, the supernatants were collected. The resulting pellets were washed three times at 65°C for 10 min with a solution consisting of 100 mM KCl, 20 mM Tris-HCl (pH 7.5), followed by incubation on ice for 6 min for precipitation each cycle. All supernatants were combined for free DNA measurement. The final pellets were digested with proteinase K, and 80 μl of BSA (5 mg/ml) was added to each sample. Quantification of both DPC-bound DNA and free DNA was performed by the PicoGreen assay kit.

### RADAR assay {#S22}

The RADAR assay for TOP1cc was performed following the published protocol ([@R14]). Briefly, cells were seeded in 6-well plates and treated with 2.5-10 μM CPT. After treatment, cells were lysed in 0.8 mL MB (6M GTC, 10 mM Tris-HCl, pH 6.5, 20 mM EDTA, 4% Triton X-100, 1% Sarkosyl and 1% dithiothreitol). Nucleic acids were precipitated out of the lysate by adding half volume (0.4 mL) of 100% ethanol, incubating at −20 for 5 min, and centrifuging at maximum speed for 15 min. After 2 washes in 75% ethanol, pellets were resuspended in 0.2 mL of 8 mM NaOH without drying. For immunodetection, a small portion of the lysates were diluted in Tris-buffered saline \[10mM Tris (pH 7.5), 150mM NaCl\] for a final volume of 0.2 mL, which was then slot blotted onto a nitrocellulose membrane with the Bio-Rad BioDot SF. Band intensities were analyzed with the online ImageJ software and normalized to the amount of loaded DNA. Antibodies used in this assay were rabbit anti-TOP1 (Bethyl, 1:2000) and mouse anti-dsDNA (Abcam, 1:2000).

### Clonogenic survival assay {#S23}

Cells at 50% confluency were treated with formaldehyde for 2 hours in serum-free media and then seeded in duplicates in 6-well plates. After 10 to 14 days in regular medium, colonies were fixed with 6% glutaraldehyde (v/v) and stained with 0.5% crystal violet (w/v) for visualization.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S24}
---------------------------------------

Statistical analysis was performed using built-in functions in GraphPad Prism Version 8. For experiments involving three or more groups but only one variable, one-way ANOVA analysis was conducted to broadly determine if the means of all groups are all the same through an F-test with p \< 0.05 being considered significant. If significant, further Tukey-Cramer test was performed for comparisons between any two groups. Analysis involving only two groups was carried out using Student t tests with p \< 0.05 being considered statistically significant. Symbols for different significance levels are assigned as the following: \* for p \< 0.05; \*\* for p \< 0.01; \*\*\* for p \< 0.001; \*\*\*\* for p \< 0.0001; NS for not significant. All data for measured variables were expressed as means ± SD as indicated. Sample size was n ≥ 3 containing both biological and experimental replicas, as indicated.

DATA AND CODE AVAILABILITY {#S25}
--------------------------

No new datasets or code were generated in this paper.
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![Schematic Illustration of the ARK Assay\
Cells are lysed with 5.6 M GTC to disrupt the noncovalent association between DNA and proteins. Free DNA and DPC-associated DNA are recovered by ethanol precipitation. The DNA-DPC pellet is dissolved in SDS buffer to further eliminate noncovalent DNA-protein interactions and to denature the proteins. The subsequent addition of KCl results in the precipitation of SDS-bound proteins along with DPC-associated DNA, while free DNA remains soluble. The DPCs that are recovered are digested with proteinase K to remove the protein adducts, resulting in the release of DPC-associated DNA for the quantification and calculation of the DPC coefficient.](nihms-1553315-f0001){#F1}

![ARK Assay Optimization Yielded Significantly Reduced Background and Increased Sensitivity\
(A) Reduction of DPC coefficient background by pre-warming lysis buffer to 55°C (versus room temperature \[RT\]) and by syringe shearing after DPC precipitate is dissolved in 1% SDS buffer. The background DPC levels before these optimizations were set to 100% for comparison purposes.\
(B) Impact of RNA removal on DPC fold induction reading from HeLa and TK6 cells exposed to 200 μM FA (2 h). DNA samples recovered after proteinase K digestion were treated and mock-treated with RNase A-T1 mix and subsequently measured by PicoGreen quantification.\
(C) Effect of BSA in PicoGreen DNA measurement. Recovered DNA samples after proteinase K digestion were subjected to PicoGreen quantification in the presence or absence of the indicated amount of BSA.\
(D) Parallel comparison of assay readout between the K-SDS and ARK methods. Cells were treated with 400 μM FA for 2 h. DPC levels are represented by fold induction compared to mock-treated cells.\
Number of biological repeats: n = 6 for (A), n = 3 for (B)--(D). The error bars depict standard deviations.](nihms-1553315-f0002){#F2}

![Detection of Nonenzymatic DPCs by the ARK Assay\
(A) Dose response of 293A, HeLa, and TK6 cells exposed to the indicated concentrations of FA for 2 h. DPC fold inductions were calculated by normalizing DPC-associated DNA to that of mock treatment.\
(B) DPC repair time course in 293A, HeLa, and TK6 cells exposed to 400 μM FA treatment for 2 h. DPC coefficient of each cell line after treatment is set as 100%.\
n = 4 for (A) and n = 6 for (B). The error bars depict standard deviations.](nihms-1553315-f0003){#F3}

![Detection of Enzymatic DPCs Induced by Topoisomerase Inhibitors with the ARK Assay\
(A) 293A, HeLa, and TK6 cells were exposed to various doses of CPT for 1 h and analyzed by the ARK assay to generate DPC fold induction by normalizing the DPC coefficient of each sample against that of the mock-treated control.\
(B) HeLa, 293A, and TK6 cells were exposed to various doses of etoposide for 1 h and analyzed by the ARK assay to generate the DPC fold induction by normalizing the DPC coefficient of each sample against that of the mock-treated control.\
Each data point was generated from no less than 5 biological repeats with triplication. The error bars depict standard deviations.](nihms-1553315-f0004){#F4}

![Analysis of DPC Repair Deficiency in *SPRTN* and *TDP1/TDP2* Knockout Mutants with the ARK Assay\
(A) Removal of DPCs in wild-type TK6 cells and 2 SPRTN knockout derivatives (*KO1* and *KO2*). Cells were exposed to 400 μM FA for 2 h. DPC coefficients were determined for each cell line at the indicated time points and normalized against the 0 time point to arrive at the percentages of DPCs remaining.\
(B) DPC accumulation in wild-type TK6 cells and 2 SPRTN knockout derivatives continuously exposed to low-dose FA (50 μM) for 12 and 24 h.\
(C) DPC accumulation in wild-type TK6 cells and a *TDP1/2*^−/−^ double-knockout derivative continuously exposed to CPT (75 nM) for 12 and 24 h.\
Each data point in the plots and in the bar graphs was derived from no less than 5 biological repeats with duplicates or triplicates. One-way ANOVA analyses for the three time points 6, 9, and 24 h generated p \< 0.0001 in (A) for the F-test and interested pairwise Tukey test results are indicated. Number of biological repeats with triplication = 3. The error bars depict standard deviations.](nihms-1553315-f0005){#F5}

![Parallel Comparison of Assay Readout between the RADAR and ARK Assays\
(A) RADAR assay of 293A, HeLa, and TK6 cells treated with 10 μM CPT for 1 h. Upper panel: representative slot blot of DPC samples visualized by an anti-TOP1 antibody as performed by the standard RADAR assay. Lower panel: slot blot (using anti-double-stranded DNA \[dsDNA\]) of DNA isolated from corresponding samples in the upper panel.\
(B) Relative TOP1-DPC induction by normalizing the TOP1-DPC chemiluminescent signal to the corresponding DNA signal in (A). The background levels of the mock-treated sample (Ctrl) for each cell line were set to 1.\
(C) ARK detection of TOP1-DPC from identical cell samples used in (A).\
(D) DPC isolates were prepared by the ARK assay protocol from identical cell samples used in (A) and blotted with an anti-TOP1 antibody (upper panel). Lower panel: slot blotting of DNA isolated from corresponding samples in the upper panel.\
The number of biological repeats ≥3. The error bars depict standard deviations.](nihms-1553315-f0006){#F6}

![Removal of DPCs in Fanconi Anemia and NER Mutants\
(A) Clonogenic survival of HeLa wild-type, *XPA*^−/−^, FANCL^−/−^, XPA^−/−^/*FANCL*^−/−^ cells treated with FA.\
(B) Removal of DPCs in wild-type HeLa cells and other indicated knockout derivatives. Cells were exposed to 500 μM FA for 2 h. DPC coefficients were determined for each cell line at indicated time points and normalized against the 0 time point to arrive at the percentages of DPC remaining.\
(C) Left panel: DPC accumulation in wild-type HeLa cells and other indicated knockout derivatives continuously exposed to low-dose FA (75 μM) for 6 and 12 h; right panel: analysis of FA-induced DPC accumulation among HeLa cells examined in the left panel after formaldehyde treatment for 6 and 12 h, respectively. Accumulated DPCs are calculated from the DPC coefficient at the selected time point with a deduction of background level (time 0) for corresponding HeLa cell lines.\
Number of biological repeats with duplication: n = 2 for (A), n = 4 for (B) and (C). The error bars depict standard deviation. One-way ANOVA analyses for the indicated time points (9 and 18 hr in B; 6 and 12 h in C) generated p \< 0.0002 for the F-test, and interested pain/vise Tukey test results are displayed.](nihms-1553315-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                           SOURCE                                                                                                                                                 IDENTIFIER
  ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------
  Antibodies                                                                                                                                                                                                                           
  anti-Tdp2 antibody                                                            Bethyl Laboratories                                                                                                                                    Cat\# A302-737A; RRID:AB_10631698
  anti-TOP1 antibody                                                            Bethyl Laboratories                                                                                                                                    Cat\# A302-589A; RRID:AB_2034865
  anti-dsDNA antibody                                                           Abcam                                                                                                                                                  Cat\# ab27156; RRID:AB_470907
  anti-XPA antibody                                                             Lab Vision                                                                                                                                             Cat\# MS-650-P0; RRID:AB_142101
  anti-vinculin antibody                                                        Sigma-Aldrich                                                                                                                                          Cat\# V9131; RRID:AB_477629
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                                                        
  Formaldehyde (FA)                                                             Sigma-Aldrich                                                                                                                                          Cat\# F8775
  Guanidine thiocyanate (GTC)                                                   Sigma-Aldrich                                                                                                                                          Cat\# G9277
  Camptothecin (CPT)                                                            Sigma-Aldrich                                                                                                                                          Cat\# 390238
  PicoGreen                                                                     Thermo Fisher Scientific                                                                                                                               Cat\# P7589
  MycoAlert                                                                     Lonza                                                                                                                                                  Cat\# LT07-218
  Etoposide (ETO)                                                               Abcam                                                                                                                                                  Cat\# ab120227
  Critical Commercial Assays                                                                                                                                                                                                           
  GeneArt Seamless Cloning and Assembly Kit                                     Thermo Fisher Scientific                                                                                                                               Cat\# A13288
  Neon Transfection Kit                                                         Thermo Fisher Scientific                                                                                                                               Cat\# MPK10025
  Experimental Models: Cell Lines                                                                                                                                                                                                      
  293A                                                                          Invitrogen                                                                                                                                             Cat\# R70507
  TK6                                                                           Dr. Shunichi Takeda                                                                                                                                    N/A
  TK6 SPRTN−/−                                                                  This paper                                                                                                                                             N/A
  TK6 TDP1−/−                                                                   [@R11]                                                                                                                                                 N/A
  TK6 TDP1/2−/−                                                                 This paper                                                                                                                                             N/A
  HeLa                                                                          ATCC                                                                                                                                                   ATCC CCL-2; RRID:CVCL_0030
  HeLa XPA−/−                                                                   This paper                                                                                                                                             N/A
  HeLa FANCL−/−                                                                 [@R46]                                                                                                                                                 N/A
  HeLa XPA−/−;FANCL−/−                                                          This paper                                                                                                                                             N/A
  Oligonucleotides                                                                                                                                                                                                                     
  SPRTN gRNA: TCAAAAGGGGTTCGCTGAGACGG                                           This paper                                                                                                                                             N/A
  TDP2 gRNA: CCAAGAAGGTCCAAACTTCG                                               This paper                                                                                                                                             N/A
  XPA gRNA: GGCGGCTTTAGAGCAACCCG                                                This paper                                                                                                                                             N/A
  TK6 Primers F/R 1-8 see [Table S1](#SD1){ref-type="supplementary-material"}   This paper                                                                                                                                             N/A
  Recombinant DNA                                                                                                                                                                                                                      
  DT-A-pA/loxP/PGK- Neo^R^-pA/loxP                                              Laboratory for Animal Resources and Genetic Engineering, Center for Developmental Biology, RIKEN Kobe, <http://www2.clst.riken.jp/arg/cassette.html>   Cassette \#16
  DT-A-pA/loxP/PGK-Puro^R^-pA/loxP                                              [@R29]                                                                                                                                                 N/A
  pX330-U6-Chimeric_BB-CBh-hSpCas9                                              [@R4]                                                                                                                                                  Addgene Cat\# 42230; RRID:Addgene_42230
  lentiGuide-Puro                                                               [@R40]                                                                                                                                                 Addgene Cat\# 52963; RRID:Addgene_52963
  lentiCas9-Blast                                                               [@R40]                                                                                                                                                 Addgene Cat\# 52962; RRID:Addgene_52962
  Software and Algorithms                                                                                                                                                                                                              
  ImageJ                                                                        ImageJ                                                                                                                                                 <https://imagej.nih.gov/ij/>; RRID:SCR_003070
  GraphPad Prism 8                                                              GraphPad                                                                                                                                               <https://www.graphpad.com/scientific-software/prism/>; RRID:SCR_002798

###### Highlights

-   A sensitive assay for the global measurement of DNA-protein crosslinks (DPCs)

-   Stringent DPC purification scheme improves DPC detection and minimizes background signals

-   Assay is capable of both enzymatic and nonenzymatic DPC detections

-   DPC repair is impaired in Fanconi anemia pathway-deficient cells
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